Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
10.1097/CM9.0000000000000196
- Author:
Chao ZHU
1
;
Yun-Hong YOU
;
Ke-Ke NIE
;
You-Xin JI
Author Information
1. Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
- Publication Type:Case Reports
- MeSH:
Acrylamides;
therapeutic use;
Aged;
Aniline Compounds;
therapeutic use;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
genetics;
Crown Ethers;
therapeutic use;
ErbB Receptors;
genetics;
metabolism;
Female;
Humans;
Lung Neoplasms;
drug therapy;
genetics;
Mutation;
genetics;
Quinazolines;
therapeutic use
- From:
Chinese Medical Journal
2019;132(9):1115-1116
- CountryChina
- Language:English
